Oncology (all articles)
Podcast | Overview of checkpoint inhibitors for general practitioners.
6 Jul, 2022 | 11:29h | UTC#342 Checkpoint Inhibitors – The Curbsiders
Network M-A | High-dose radiotherapy or androgen deprivation therapy as treatment intensification for localized prostate cancer.
6 Jul, 2022 | 11:09h | UTCHigh-dose Radiotherapy or Androgen Deprivation Therapy (HEAT) as Treatment Intensification for Localized Prostate Cancer: An Individual Patient–data Network Meta-analysis from the MARCAP Consortium – European Urology (link to abstract – $ for full-text)
Commentary on Twitter
New In Press: High-dose Radiotherapy or Androgen Deprivation Therapy (HEAT) as Treatment Intensification for Localized Prostate Cancer: An Individual Patient–data Network Meta-analysis from the MARCAP Consortiumhttps://t.co/rZnBjvccNe@AmarUKishan @DrSpratticus et al. pic.twitter.com/uCrg7sRmsS
— European Urology (@EUplatinum) April 25, 2022
The multicenter cancer of pancreas screening study: impact on stage and survival.
5 Jul, 2022 | 11:46h | UTC
Commentary on Twitter
? The Cancer of Pancreas Screening (CAPS) program achieves early #PancreaticCancer detection and long-term survival with surveillance ➡️ https://t.co/flqUtSvkcg #JCO #pancSM @mggoggins pic.twitter.com/wj6DMXclVC
— Journal of Clinical Oncology (@JCO_ASCO) June 30, 2022
M-A | Risk factors of clinically relevant postoperative pancreatic fistula after pancreaticoduodenectomy.
5 Jul, 2022 | 11:32h | UTCGuideline | Malignancy risk stratification for solitary pulmonary nodule.
4 Jul, 2022 | 12:33h | UTCRCT | Effect of levofloxacin on the efficacy and adverse events in intravesical Bacillus Calmette-Guerin treatment for bladder cancer.
4 Jul, 2022 | 12:19h | UTCRCT | CT vs. [18F]FDG-PET-CT for persistent or recurrent neutropenic fever in high-risk patients.
4 Jul, 2022 | 12:21h | UTC[18F]FDG-PET-CT compared with CT for persistent or recurrent neutropenic fever in high-risk patients (PIPPIN): a multicentre, open-label, phase 3, randomised, controlled trial – The Lancet Haematology (link to abstract – $ for full-text)
Commentary on Twitter
NEW research: [18F]FDG-PET-CT resulted in more frequent antimicrobial rationalisation than CT in patients w/ haem diseases & persistent/recurrent high-risk neutropenic fever after chemotherapy. Results of the ph3 RCT PIPPIN #radonc #hemonc https://t.co/isOPFZVVpY pic.twitter.com/PVd8yFy7Ck
— The Lancet Haematology (@TheLancetHaem) June 29, 2022
Phase 1 single-arm study | Oncolytic DNX-2401 virus for pediatric diffuse intrinsic pontine glioma.
4 Jul, 2022 | 12:08h | UTCOncolytic DNX-2401 Virus for Pediatric Diffuse Intrinsic Pontine Glioma – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary: Oncolytic Virus Infusion Promising as Brain-Stem Glioma Treatment — Phase I trial shows encouraging OS in children with diffuse intrinsic pontine glioma – MedPage Today (free registration required)
2022 Guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19.
1 Jul, 2022 | 11:50h | UTCRelated:
UEG and EAES rapid guideline on transanal total mesorectal excision for rectal cancer.
1 Jul, 2022 | 11:33h | UTC
RCT: Oxaliplatin (3 months vs. 6 months) with 6 months of Fluoropyrimidine as adjuvant therapy in patients with stage II/III colon cancer.
1 Jul, 2022 | 10:59h | UTC
RCT: Effect of a community health worker intervention on acute care use, advance care planning, and patient-reported outcomes among adults with advanced stages of cancer.
1 Jul, 2022 | 10:58h | UTCEffect of a Community Health Worker Intervention on Acute Care Use, Advance Care Planning, and Patient-Reported Outcomes Among Adults With Advanced Stages of Cancer: A Randomized Clinical Trial – JAMA Oncology (free for a limited period)
See also: Visual Abstract
RCT: The effect of enhanced recovery after minimally invasive esophagectomy.
1 Jul, 2022 | 10:56h | UTCRelated:
Complete List of Enhanced Recovery After Surgery (ERAS) Society Guidelines
Visual abstract: ASO Visual Abstract: Guide to Enhanced Recovery for Cancer Patients Undergoing Surgery—ERAS and Esophagectomy
Enhanced recovery after surgery (ERAS) programs for esophagectomy – Journal of Thoracic Disease
RCT: Effect of Apatinib plus Pegylated Liposomal Doxorubicin vs. Pegylated Liposomal Doxorubicin alone on platinum-resistant recurrent ovarian cancer.
1 Jul, 2022 | 10:37h | UTCSee also: Visual Abstract
RCT: Atezolizumab with neoadjuvant anti–human epidermal growth factor receptor 2 therapy and chemotherapy in human epidermal growth factor receptor 2–positive early breast cancer.
1 Jul, 2022 | 10:28h | UTCCommentary: Atezolizumab Does Not Improve pCR in HER2-Positive Early Breast Cancer – OncLive
Commentary on Twitter
Presented at #ESMO VP6, IMpassion050 is now published on JCO. The addition of atezo to neoadjuvant ddAC-T+HP doesn’t increase pCR rates in HER2+ EBC, neither in ITT (left) nor PD-L1+ (right). Significant increase in toxicity with atezo, including 5 deaths.https://t.co/fL6mEjKTTS pic.twitter.com/2fYStkh8Zt
— Paolo Tarantino (@PTarantinoMD) June 28, 2022
Opinion | Renaming Gleason Score 6 prostate to noncancer: a flawed idea scientifically and for patient care.
30 Jun, 2022 | 10:44h | UTCOriginal Opinion Paper: Low-Grade Prostate Cancer: Time to Stop Calling It Cancer – Journal of Clinical Oncology
Joint final report of Phase III trials demonstrate positive outcomes from combination of PCV chemotherapy and RT in patients with anaplastic oligodendroglial tumors.
30 Jun, 2022 | 10:16h | UTC
ASCO Guideline Update: Biomarkers for systemic therapy in metastatic breast cancer.
29 Jun, 2022 | 11:40h | UTC
Commentary on Twitter
‼️ ? @ASCO guideline update published in #JCO by @lynnhenrymd et al: Biomarkers for #SystemicTherapy in Metastatic #BreastCancer ➡️ https://t.co/qAzT9WNKTF #bcsm #biomarkers @AngieDemichele pic.twitter.com/3WtAt8TK5w
— Journal of Clinical Oncology (@JCO_ASCO) June 27, 2022
Systematic Review: Trastuzumab Deruxtecan-induced interstitial lung disease/pneumonitis in ERBB2-positive advanced solid malignancies.
29 Jun, 2022 | 10:59h | UTC
RCT: Maintenance Taxanes vs. surveillance in women with advanced ovarian/tubal/peritoneal cancer.
29 Jun, 2022 | 10:57h | UTCPhase III Randomized Trial of Maintenance Taxanes Versus Surveillance in Women With Advanced Ovarian/Tubal/Peritoneal Cancer: A Gynecologic Oncology Group 0212:NRG Oncology Study – Journal of Clinical Oncology (link to abstract – $ for full-text)
Consensus Guideline: Diagnosis and treatment of Merkel cell carcinoma.
28 Jun, 2022 | 11:07h | UTC
Study: Biochemical failure is not a surrogate end point for overall survival in recurrent prostate cancer.
28 Jun, 2022 | 10:32h | UTCBiochemical Failure Is Not a Surrogate End Point for Overall Survival in Recurrent Prostate Cancer: Analysis of NRG Oncology/RTOG 9601 – Journal of Clinical Oncology (link to abstract – $ for full-text)
Phase 2 RCT: Durvalumab plus Olaparib in previously untreated, platinum-ineligible patients with metastatic urothelial carcinoma.
28 Jun, 2022 | 10:31h | UTCDurvalumab Plus Olaparib in Previously Untreated, Platinum-Ineligible Patients With Metastatic Urothelial Carcinoma: A Multicenter, Randomized, Phase II Trial (BAYOU) – Journal of Clinical Oncology (link to abstract – $ for full-text)
Commentary from the author on Twitter
Results from Durva+/-Olaparib in 1L platinum ineligible mUC published in JCO. No benefit in ITT, but prolonged PFS in HRRm patients. Worthy of further investigation. Tough trial to do, made possible by great international team. @MSKCancerCenter @JCO_ASCO https://t.co/9hQNYoR5OE pic.twitter.com/bz1wTAXp7K
— Jonathan Rosenberg MD (@DrRosenbergMSK) June 24, 2022
Consensus Statement: First-line PARP inhibitor maintenance for advanced, high-grade serous and endometrioid tubal, ovarian, and primary peritoneal cancers.
27 Jun, 2022 | 11:34h | UTC
RCT: Efficacy of Ipilimumab vs. FOLFOX in combination with Nivolumab and Trastuzumab in patients with previously untreated ERBB2-positive esophagogastric adenocarcinoma.
27 Jun, 2022 | 11:11h | UTCEfficacy of Ipilimumab vs FOLFOX in Combination With Nivolumab and Trastuzumab in Patients With Previously Untreated ERBB2-Positive Esophagogastric Adenocarcinoma: The AIO INTEGA Randomized Clinical Trial – JAMA Oncology (free for a limited period)
Commentary: AIO INTEGA Provides Further Support for Immunotherapy in Patients With Advanced ERBB2-Positive Gastroesophageal Adenocarcinoma – JAMA Oncology (free for a limited period)